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Abstract
The continued success of genome sequencing projects has resulted in a wealth of information, but
40-50% of identified genes correspond to hypothetical proteins or proteins of unknown function. The
Functional Annotation Screening Technology by NMR (FAST-NMR) screen was developed to
assign a biological function for these unannotated proteins with a structure solved by the Protein
Structure Initiative. FAST-NMR is based on the premise that a biological function can be described
by a similarity in binding sites and ligand interactions with proteins of known function. The resulting
co-structure and functional assignment may provide a starting point for a drug discovery effort.
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The completion of the human genome project is spurring tremendous progress in cell biology,
development, evolution and physiology [1]. The expanding number of protein structures
emerging from the Protein Structure Initiative (PSI) is contributing to these advancements
[2]. As of January 2007, the sequencing of 607 genomes has been completed with 1676 ongoing
projects. Also, nearly 2,500 protein structures have been solved by PSI [3,4]. Drug discovery
is benefiting from these successes through the identification of novel therapeutic targets and
the development of new tools to optimize chemical leads [5-7]. As an example, the
identification of novel anti-infectious targets may aid in avoiding common mechanisms of
resistance and extend the lifetime of new antibiotics [8,9].
An underlying challenge to capitalizing on genome sequencing efforts is the abundance of
hypothetical proteins, proteins that lack a functional annotation. Our recent analysis of various
bacterial genomes from the August 2007 Gold release shows that, even with improved
computational methods, approximately 40% of bacterial proteins have not been assigned to a
functional category (Figure 1) [3]. There are more than 11,000 proteins from the ten bacterial
organisms listed in Figure 1 that lack a functional annotation. Considering this list is only from
a small segment of currently sequenced genomes, the prospect of obtaining experimental
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functional information for all hypothetical proteins identified from completed and ongoing
sequencing efforts is a daunting proposition. Valuable information is hidden among this
multitude of unannotated proteins that could be associated with cell viability, biofilm
formation, infection, and pathogenesis. These proteins may provide key information for
developing new antibiotics, where drug discovery efforts would benefit greatly from new
functional annotations methodology.
Most high-throughput experimental methods to assign function have focused primarily on
generating knockout libraries to analyze cell phenotypes, monitoring changes in gene
expression or determining protein interaction maps [10-12]. These methods generally do not
provide functional information for a specific protein without additional detailed bioinformatics
[13,14]. Global sequence similarity is routinely used to infer the function of hypothetical
proteins, despite analysis that suggest error rates are as high as 30% [15,16]. Conversely,
amino-acid residues associated with the active-sites and biological activities of proteins are
stable evolutionarily relative to the remainder of the protein's sequence and provide an
alternative approach for functional annotation [17,18]. A basic definition of biological function
is derived from a protein's interaction with small molecules and other biomolecules. Thus, the
identification of functional ligand(s), an active site and a corresponding protein-ligand co-
structure is instrumental to defining a function for a hypothetical protein. The comparison and
prediction of ligand binding sites from both structural and sequence information is a proven
approach for functional assignments of proteins [19]; however, these predictions may lead to
ambiguous or incorrect annotations [20,21]. A combination of experimental protein-ligand
binding data with bioinformatic analysis will minimize the uncertainties commonly associated
with pure computational approaches.
FAST-NMR (Functional Annotation Screening Technology by NMR) provides functional
information for hypothetical proteins by experimentally characterizing and analyzing ligand
binding sites [22]. Once the functional ligands [23] are identified and the binding site is located,
a co-structure is obtained. A functional assignment is deduced by comparing the ligand-defined
active-site from FAST-NMR to a database of protein-ligand binding sites for proteins of known
function using CPASS (Comparison of Protein Active-Site Structures) [24]. The information
obtained from FAST-NMR furthers our understanding of the basic biological role of
hypothetical proteins and provides a potential starting point for drug discovery. A summary of
some common applications for the functional annotation of proteins of unknown proteins and
a comparison to our FAST-NMR method are listed in Table 1.
The FAST-NMR Method
FAST-NMR was developed to assign biological functions to hypothetical protein structures
solved by PSI. Recent statistical analysis indicates that ~20-50% of protein structures
determined by PSI may be amenable to analysis by NMR [25,26]. The Protein Structure
Database (PDB) currently contains ~2,200 proteins of unknown function [27]. These proteins
tend to be “orphaned” from any further functional analysis because of a complete absence of
information to guide a research project [28-31]. These orphaned proteins are ideal targets for
analysis by FAST-NMR. An assigned 1H-15N Heteronuclear single quantum coherence
(HSQC) NMR spectrum and a corresponding structure for a protein of unknown function are
the primary requirements for the FAST-NMR methodology. In general, high-resolution NMR
structures and assignments can be routinely obtained for proteins <25 kDa using standard 13C
and 15N protein labeling techniques [32,33]. This molecular-weight upper limit may be
extended by upwards of 900 kDa [34-40] by the application of deuterium labeling, specific
methyl labeling and Transverse Relaxation-Optimized NMR Spectroscopy (TROSY)-based
experiments [41-43].
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The FAST-NMR assay applies a tired approach to screening, where an overview of the
methodology is illustrated in Figure 2. The first 1D 1H line-broadening (LB) experiments are
amenable for screening a large number of compounds in a relatively short time (< 10 minutes/
sample) and requiring a minimal amount of unlabeled protein material (< 0.1 mgs/sample).
Only positive “hits” from the LB experiments are further screened in 2D 1H-15N HSQC spectra.
In this manner, the tiered approach minimizes resources and increases throughput by funneling
only the most promising candidates forward to the more resource intensive 2D 1H-15N HSQC
experiments.
In the first LB experiment, the formation of a protein-ligand complex can be determined by
monitoring changes in the ligand's spectrum. Binding of the ligand to the protein causes line
width broadening that may result in the complete disappearance of the ligand's NMR peak(s).
This is caused by the large differences in molecular-weight and correlation time (τc, time it
takes the molecule to rotate one radian) between the protein and small molecule. In the second
NMR experiment, changes in the protein's NMR spectrum are followed to further confirm a
specific interaction and identify a potential binding site. Ligand binding causes local
environmental changes in the protein resulting in the observation of chemical shift
perturbations (CSPs) in the 2D 1H-15N HSQC spectrum. Since each peak in the HSQC
spectrum has been sequentially assigned to a specific amino acid in the protein's sequence, the
CSPs can be mapped onto the surface of the protein. A consensus clustering of CSPs identifies
the location of the ligand binding site. A lack of CSPs or a random distribution of CSPs over
the protein's surface indicates non-specific binding of the ligand to the protein.
A rapid protein-ligand co-structure is determined by combining the experimental CSPs with
molecular modeling. AutoDock [44] has been demonstrated to outperform two other well-
known docking tools, FlexX and DOCK [45] in a virtual screen, and is currently the most cited
of molecular modeling applications [46]. The experimental CSPs define a grid used by
AutoDock to guide the ligand docking into the NMR defined binding site. Our AutoDockFilter
(ADF) program is then used to filter the AutoDock conformers and select a pose that best fits
the CSPs. In general, amino acid residues with the largest CSPs are expected to be closer to
the bound ligand relative to residues with smaller CSPs. The best-structure is then used to
determine a ligand-defined binding site for CPASS analysis. CPASS identifies ligand-defined
binding sites for proteins of known function from a PDB derived database that best matches
the sequence and structural details of the ligand-defined binding site determined by FAST-
NMR. A similarity between these ligand-defined binding sites infers a function that can be
assigned to the hypothetical protein.
Functional Chemical Library
A critical component of the FAST-NMR methodology is the functional chemical library [47]
(Figure 3). The library contains compounds with demonstrated protein affinity and, as
completely as possible, covers the diversity of biological activity. The library is screened for
binders by NMR to probe for protein function and includes known drugs, inhibitors and protein
substrates that target a diverse set of protein functions covering a range of structural chemical
classes. This list includes amino-acids, carbohydrates, co-factors, fatty-acids, hormones,
metabolites, neurotransmitters, nucleic acids and vitamins. Importantly, the distribution of
chemical and physical properties for the compounds in the functional library is similar to drug-
like molecules (MW < 500 Da, number of heteroatoms < 10, cLogP < 5, and number of rings
< 2). This indicates that compounds identified as binders in a FAST-NMR screen may also be
useful starting points for structure-based drug design, if the hypothetical protein is identified
as a valuable therapeutic target.
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The design of the functional chemical library was optimized for screening by NMR. The
compounds are soluble in water, do not aggregate, precipitate or react in mixtures and have
unique NMR resonances for ready identification that avoids deconvolution. The selection
process for the compounds in the functional library was extensive and based on a number of
criteria: known biological activity, the existence of a co-structure in the Protein Database (PDB)
[48], the likelihood of aqueous solubility (≥ 100μM), purity (≥90%), commercial availability
(≥ 5mg) and cost (≤ $32). Each of the compounds are dissolved in D6-DMSO or D2O and
stored in 96-well plates in a dessicator in a −80°C freezer. Compounds are screened in mixtures
to further increase throughput while minimizing resources. The mixtures were designed to
contain 3-4 compounds based on our statistical analysis of the optimal mixture size for NMR
screens [49].
CPASS
CPASS incorporates a computer program with a structural database to compare ligand binding
sites and provide a putative function for hypothetical proteins screened by FAST-NMR [24].
CPASS is a structure-based functional annotation program that differs from a variety of 3D
template or sequence-based annotation programs (for a review see Watson et al. (2005) [50])
routinely used to predict ligand binding sites and protein function. These programs attempt to
predict the location of ligand binding sites using various sequence and structure heuristics.
Instead, CPASS aligns experimentally determined ligand-defined binding sites from FAST-
NMR and the PDB using sequence and structural descriptors. Simply, CPASS identifies
matches between functionally relevant ligand-binding sites to leverage an annotation.
CPASS may also aid the development of selective chemical leads. Drug toxicity is a common
cause of clinical failures [51], where this toxicity is associated with non-specific in vivo protein
activity [52]. In practice, it is not possible to screen against every potential protein target that
may bind a chemical lead. Instead, a small panel of homologous proteins is used in secondary
assays to infer compound specificity. The proteins are generally selected based on global
sequence similarity to the protein target of interest. Unfortunately, there are also other proteins
that share a high similarity in the ligand binding site that may lack global sequence similarity.
Our previous CPASS analysis of ATP binding proteins indicates a significant cluster of proteins
with sequence similarity < 20% that had high CPASS similarity of > 40% [24]. Similarly, we
identified two alanine racemases that share only an 8% sequence similarity, but had essentially
identical PLP binding sites. Clearly, proteins that share high ligand binding site similarity, but
lack global sequence similarity pose serious risks of causing toxic side-effects in clinical trials
unless identified using applications like CPASS.
Protein-Ligand Database
The CPASS database is continuously updated from the PDB and contains proteins in complex
with small molecules, peptides, and oligonucleotides. Proteins may bind one ligand, multiple
ligands, or the same ligand more than once. Each unique ligand-binding site (< 80% sequence
similarity, distinct ligand) is incorporated into the CPASS database. There are ~55,000 protein-
ligand binding sites currently present in the PDB, where ~21,000 are unique. These ligand-
defined binding sites include all the amino acids in the protein sequences that have at least one
atom within 6 Å of any atom of the ligand. Both the structure coordinates and the sequence
identity are then used in a comparison with ligand-defined binding sites from other proteins.
The ligand structure is not included in the ligand-defined binding site, but is used to classify
the type of binding site (i.e. ATP binding site, FAD binding site, etc).
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Similarity Scoring Function
Although the CPASS program will allow the user to search binding-sites based on the type of
ligand that defines the binding site, it is not required. The comparison can be made against all
ligand-defined binding sites present in the CPASS database or any ligand-type subset. The
CPASS scoring function is based on the simultaneous structure and sequential alignments of
two ligand-defined binding sites. A BLOSUM62 probability function weighted by root-mean
square distance (rmsd) is used to compare the similarity of spatially aligned residues:
Active site a contains n residues and is compared to active site b of m residues from the CPASS
database. pi,j is the BLOSUM62 probability for replacement of amino acid i from active site
a with residue j from active site b, Δrmsdi,j is the corrected root-mean-square-difference in the
Cα positions between the residues i and j, and dmin/di is the ratio of the shortest distance to an
atom in the ligand from any atom in the residue i. This last term minimizes boundary effects.
Small structural changes may result in residues entering or leaving the 6Å cut-off used to define
a ligand-defined binding site. This may result in relatively large changes in the scoring function
due to modest structural fluctuations.
The similarities between the active sites are then calculated by:
where S is the similarity score, Sab is the similarity score for the protein target against an active
site from the CPASS database, and Saa is the similarity of the active site compared to itself
used for normalization. In effect, a percent similarity is determined based on how well the
sequence and structures of the two ligand-binding sites overlap. The scoring function is not
symmetrical since it depends on the size of the binding site.
CPASS Functional Prediction of Hypothetical Proteins
To illustrate further the utility of CPASS, a recent protein deposited in the PDB was chosen
that only had a putative functional annotation. A human protein (PDB-ID 2PL3) was tentatively
assigned as a probable ATP-dependent RNA helicase DDX10 and the structure contained a
bound ADP molecule. CPASS analysis identified PDB-ID 2OXC as having the highest
similarity (56.26%). Both proteins bind ADP and are hypothetical DEAD domains. The highest
CPASS similarity score (50.30%) to a protein of known function was to PDB-ID 1XTJ, a
DECD to DEAD mutation of human UAP56, which is also in complex with ADP [53].
Recently, the UAP56 protein has been shown experimentally to exhibit RNA-stimulated
ATPase activity and ATP-dependent RNA helicase activity [54]. Thus, the CPASS analysis
supports the prior putative assignments of hypothetical proteins 2PL3 and 2OXC as ATP-
dependent RNA helicases. The top panel in Figure 4 shows the alignment of the ADP binding
sites for the 2PL3 and 1XTJ structures. This figure clearly highlights the overall similarity in
the structure and sequence alignments for the ADP binding sites.
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A crystal structure of hypothetical protein PH1320 from Pyrococcus horikoshii OT3 was
recently released by the PDB (PDB-ID 2E87). The protein is complexed to guanosine-5′-
diphosphate (GDP), but completely lacks a functional assignment and a paper describing the
structure has yet to be published. A CPASS analysis using only proteins complexed to GDP
indicates hypothetical protein PH1320 has a very high similarity (70.47%) to an Escherichia
coli elongation factor Der (PDB-ID 1MKY), an EngA homolog [55]. The bottom panel in
figure 4 clearly demonstrates the high overall similarity in the structure and sequence
alignments for the GDP binding sites between these two proteins. Hypothetical protein PH1320
shows CPASS similarity scores of 50-70% to EngB, EngC, EI-F2γ, EI-F5B, EF-Tu, EF-1α,
EF-2 and EF-G, which are also members of the elongation factor super family. Hypothetical
protein PH1320 also exhibits a slightly smaller similarity (50-60%) to Arf, Sar and Rab,
members of the small GTPase super family that regulate a diverse range of cellular events
[56]. Thus, the CPASS results suggest PH1320 is probably an elongation factor or potentially
involved in GTP signal regulation similar to either Arf, Sar or Rab.
Functional Annotation of Staphylococcus aureus Protein SAV1430
Staphylococcus aureus protein SAV1430, a hypothetical protein of unknown function, was
selected to demonstrate the FAST-NMR methodology (Figure 2). SAV1430 is a typical target
of the NorthEast Structural Genomic Consortium (NESG) [29], where a structure was
previously determined [57,58]. A Dali analysis suggested that SAV1430 has a similar topology
to a ferredoxin-like fold, but the Z-score of < 3 was insignificant [59]. The only proteins that
had any significant sequence homology to SAV1430 were other hypothetical proteins, so a
reliable function could not be assigned based on structure homology alone.
O-phospho-L-tyrosine (pTyr) was identified as one of 21 compounds that exhibited line-
broadening and chemical shift perturbations in the FAST-NMR screen with SAV1430. The
other compounds are chemically similar to pTyr and were all shown to interact in a consensus
binding-site that comprises residues I6-P10, T14-K16 and I61-V63. This binding site contains
a shallow cleft on the SAV1430 surface surrounded by relatively flat structural features
strongly suggestive of a protein-protein interaction site. A rapid structure of the pTyr-SAV1430
complex was determined using CSPs and AutoDock for CPASS analysis.
CPASS identified PDB ID 1oo4 as a significant hit (37% similarity), a Src SH2 domain
complexed with a pTyr containing peptide. SH2 domains are typically part of multi-domain
proteins involved in cell signaling and form a protein-protein complex with a kinase after
phosphorylation of a tyrosine [60]. Phosphorylation of Ser, Thr and Tyr are also common
mechanisms for regulating protein activity in bacteria [61,62]. The similarity in the
characteristics of the SAV1430 and Src SH2 ligand binding sites, and the fact that SAV1430
binds pTyr, further supports the general proposal that SAV1430 functions by forming a protein-
protein complex.
Rosetta Stone [63] analysis suggests hypothetical protein SAV0936 may be a binding partner
of SAV1430. SAV0936 exhibits 47% sequence identity with the N-terminal region of the C-
terminal NifU domain. NifU is a multi-protein complex that is a critical component of the [Fe-
S] cluster assembly pathway [64-66] and is essential for the viability of bacteria [67]. A more
exhaustive sequence analysis of SAV1430, based on the results with SAV0936, indicates the
protein shares ~30% sequence identity with the C-terminal region of the C-terminal domain
of the NifU multi-domain structure. These results imply that SAV1430 may interact with
SAV0936 to form a complex that exhibits similar activity as the full length NifU domain or
may regulate NifU activity. Thus, inhibiting the SAV1430-SAV0936 complex formation may
represent a novel target for developing next generation antibiotics.
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Conclusion
FAST-NMR provides a high-throughput approach to obtain functional assignments for
hypothetical proteins, based on experimentally-determined protein-ligand interactions. FAST-
NMR also addresses the current lack in high-throughput experimental methods to obtain
functional information [68] where current methods [14] primarily rely on sequence similarity
to confer function despite error rates as high as 30% [15,16]. FAST-NMR is based on basic
tenets of biochemistry where detailed structural information of a protein-ligand interaction is
paramount for understanding the function of a protein. Active-site residues are evolutionarily
stable relative to the remainder of the protein's sequence decreasing the likelihood of annotation
errors [17,18]. FAST-NMR compliments the success of the Human Genome Project and the
Protein Structure Initiative by providing a means to annotate functionally the rapidly expanding
number (~2,200) of hypothetical proteins currently deposited in the PDB [31]. Understanding
protein function is a paramount necessity for drug discovery programs ability to make
successful contributions to human health issues.
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Figure 1.
Functional analysis of bacterial genomes. The blue partitions are the percentage of proteins
that have assigned functional categories; the red partitions are the percentage of unannotated
proteins. Bacillus subtlus (BS); Heliobactor pylori (HP); Staphylococcus aureus (SAu);
Staphylococcus epidermis (SE); Treponema pallidum (TP); Vibrio cholerae (VC);
Streptococcus pneumoniae (SP); Streptococcus agalactiae (SAg); Bacillus anthracis (BA);
Haemophilus influenzae (HI).
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Figure 2.
Flow chart of FAST-NMR. The hypothetical proteins are screened against mixtures of ligands
from the functional chemical library. Reference 1D 1H spectra of the mixtures are compared
to those containing protein, where a hit is identified by changes in NMR line-width. Only the
ligands identified as binding in the primary screen are further assayed in the secondary
2D 1H-15N experiment. Chemical shift changes confirm a specific interaction and identify the
binding site from mapping of the CSPs on the protein's surface. The binding site and CSPs are
utilized to determine a rapid co-structure using AutoDock. This co-structure is then used by
CPASS to compare the ligand-defined binding site from the hypothetical protein to all other
protein-ligand interactions present in the PDB. A general biological function can then be
assigned based on an observed similarity to a ligand-defined binding site for a protein of known
function.
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Figure 3.
Functional chemical library. A subset of compounds from four different functional categories
from the functional chemical library is displayed. Proteins are screened against mixtures of
compounds, and these mixtures were designed to have diverse structure and function to
minimize spectral and functional overlap.
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Figure 4.
(top panel) Binding sites of 1XTJ and 2PL3. Binding-site residues for proteins (A) 1XTJ and
(B) 2PL3. Residues within 6 Å of ADP are colored blue and the ligand ADP is colored pink.
The amino acid alignment for the ADP binding sites is shown at the bottom of the figure.
(bottom panel) Binding sites of 1MKY and 2E87. Binding-site residues for proteins (A) 1MKY
and (B) 2E87. Residues within 6 Å of GDP are colored blue and the ligand GDP is colored
pink. The amino acid alignment for the GDP binding sites is shown at the bottom of the figure.
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Table 1
Summary of Applications for Protein Functional Annotation
Method Advantages/Disadvantages Website
FAST-NMR [22]
Advantages
• experimentally identifies ligands that bind protein
• experimentally identifies ligand binding site
• uses entire description of ligand binding site for functional assignment
Disadvantages
• slower than pure computational methods
• requires NMR assignments for protein
http://bionmr-c1.unl.edu
eF-seek [69]
Advantages
• compares electrostatic surfaces of functional sites to identify ligand
binding sites
Disadvantages
• results may identify multiple ambiguous ligand binding sites
• protein size limitation
• Slow (1-2 days)
http://ef-site.hgc.jp/eF-seek
JAFA [70]
Advantages
• meta-server to sequence-based methods for functional annotation
• does not require a structure
Disadvantages
• redundant with ProcFunc, but lacks structure analysis
• sequence similarity, even at the 50% level, is not sufficient to confer
function [15]
http://jafa.burnham.org
PDB-UF [27]
Advantages
• assigns E. C. number to hypothetical proteins in PDB
• uses global structural similarity to known enzymes
Disadvantages
• limited to enzymes and accuracy of E. C. assignments
• majority of proteins still unassigned
http://pdbuf.bioinfo.pl
ProcFunc [71]
Advantages
• uses a series of structure-based methods to identify ligand binding sites
and potential homologues
• comprehensive results from a variety of common methods
• fast
Disadvantages
• results may be ambiguous, inconclusive or contradictory
• reduced description of ligand binding site, 3-5 amino acids
• uncertainty in identifying ligand binding site increases uncertainty in
functional annotation
http://www.ebi.ac.uk/thornton-srv/databases/profunc
SuMo [72]
Advantages
• does not use structure or sequence similarity
• accounts for protein flexibility
http://sumo-pbil.ibcp.fr
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Method Advantages/Disadvantages Website
Disadvantages
• results may identify multiple ambiguous ligand binding sites
• uses a reduced description of ligand binding site, searches by triplets of
chemical groups
• biased to common ligand binding sites in PDB
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